- Published: July 2009
Hospital Insight Series: MRSA Infections (Europe)
- Published: December 2011
- Region: World
- 227 Pages
- Decision Resources, Inc
Methicillin-resistant Staphylococcus aureus (MRSA) is a clinically important pathogen that causes serious infections, including skin and skin structure infections, bloodstream infections, lower respiratory tract infections, and bone and joint infections. Drug resistance in MRSA and MRSA’s decreased susceptibility to IV vancomycin, the mainstay drug for the treatment of MRSA, poses significant challenges in the treatment of MRSA infections, yet provides opportunities for the uptake of other and emerging MRSA therapies in the European MRSA market.
Hospital Insight Series is a syndicated report series that analyzes the hospital antibiotic prescribing patterns for the treatment of key infections and infections caused by emerging and clinically-important pathogens, such as methicillin-resistant Staphylococcus aureus (MRSA). This report provides insight and analysis of the MRSA infection market in Europe, focusing on the key therapies for the management of MRSA infections in the hospital.
Through audit data from AMR’s Hospital Antibiotic Market Guide and primary research with infectious diseases specialists, we are able to understand dynamics of product usage, physicians’ treatment patterns, factors that influence prescribing patterns, and reactions to and perceptions of emerging and novel therapies.
Executive Summary and Key Findings
MRSA Patient Population Analysis
Physician Insight and Treatment Analysis
Novel and Emerging Therapies
|Electronic (PDF)||The report will be emailed to you. The report is sent in PDF format.||This is a single user license, allowing one specific user access to the product.|